Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

This study has been terminated.
(Low accrual; target accrual not met)
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance Identifier:
First received: October 14, 2009
Last updated: June 17, 2015
Last verified: June 2015

The number of melanoma cases has been steadily increasing over the past few decades. For many patients with metastatic melanoma, there are no effective therapies. The goal of this study is to determine whether a combination drug treatment of carboplatin, paclitaxel and temozolomide is effective in the treatment of metastatic or recurrent melanoma.

Condition Intervention Phase
Drug: paclitaxel, carboplatin, temozolomide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II of Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by New Mexico Cancer Care Alliance:

Primary Outcome Measures:
  • Objective Response Rate (ORR) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Tumor response is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1). ORR is the sum of the percentages of patients achieving complete and partial responses

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The time from treatment initiation to death by any cause

  • Safety profile and major adverse events for this combination [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    All toxicities encountered during the study will be graded according to the NCI CTCAE (Version 3.0).

  • Time to Progression [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: August 2009
Study Completion Date: June 2015
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Chemotherapy Combination
Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
Drug: paclitaxel, carboplatin, temozolomide
Carboplatin at an AUC of 5 on D1, paclitaxel at 175 mg/m2 on D1, temozolomide at 125 mg/m2 D2-D6 on a 28 day cycle.
Other Name: paclitaxel, carboplatin, temozolomide

Detailed Description:

Over the past several decades, significant research has been conducted to try to identify active chemotherapeutic agents for the treatment of melanoma. The rationale for combining taxanes and platinum agents is that both have activity in melanoma; in vitro and clinical data suggest synergy between these drugs when used in combination in a wide variety of tumors, including melanoma; and the toxicity profiles of these agents do not overlap. Temozolomide (a drug approved for the treatment of melanoma) has been combined with other drugs, including taxanes and platinums, in previous clinical trials for melanoma. Specifically, a previous phase I study of the combination of temozolomide, paclitaxel, and carboplatin in melanoma showed objective responses. The efficacy of this combination is now being studied in this phase II trial.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients with biopsy proven advanced melanoma are eligible if there is measurable disease.
  • Patients must have a life expectancy of at least 12 weeks.
  • Prior surgery, immunotherapy, minimal chemotherapy (1 drug for less than 4 months), or radiotherapy for primary tumor is acceptable but must be completed at least 4 weeks from study entry, and patient should have completely recovered from such procedures.
  • Patients must have a Zubrod performance status of 0-2.
  • Patients must sign an informed consent.
  • Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of ≥ 1500 cells/mm3, hemoglobin > 8 g/dl, platelet count ≥ 100 000/mm3.
  • Patients should have a normal hepatic function with a total bilirubin < 1.5 the upper limit of normal and SGOT or SGPT < 2 times the upper limit of normal, and adequate renal function as defined by a serum creatinine ≤ 1.5 upper limit of normal
  • Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and at least for 3 months.
  • Patients with brain metastases are eligible if they have been appropriately treated,are asymptomatic

Exclusion Criteria:

  • Pregnant women or nursing mothers are not eligible.
  • Patients must not receive any other concurrent chemotherapy or radiation during this trial.
  • Patients with severe medical problems that would interfere with the therapy are not eligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01009515

United States, New Mexico
Hematology Oncology Associates
Albuquerque, New Mexico, United States, 87106
The Cancer Center at Presbyterian
Albuquerque, New Mexico, United States, 87110
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States, 87106
Sponsors and Collaborators
New Mexico Cancer Care Alliance
Principal Investigator: Montasur Shaheen, MD University of New Mexico
  More Information

Additional Information:
No publications provided

Responsible Party: New Mexico Cancer Care Alliance Identifier: NCT01009515     History of Changes
Other Study ID Numbers: INST 0903, NCI-2011-01939
Study First Received: October 14, 2009
Last Updated: June 17, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by New Mexico Cancer Care Alliance:
skin cancer

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Alkylating Agents
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on October 06, 2015